Ophthotech Corp  

(Public, NASDAQ:OPHT)   Watch this stock  
Find more results for Kathy Wood´┐Ż
+2.65 (3.91%)
After Hours: 70.34 0.00 (0.00%)
Aug 3, 5:40PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 68.35 - 71.77
52 week 35.38 - 72.51
Open 68.35
Vol / Avg. 0.00/452,129.00
Mkt cap 2.32B
P/E     -
Div/yield     -
EPS -2.68
Shares 34.30M
Beta     -
Inst. own 89%
Aug 5, 2015
Q2 2015 Ophthotech Corp Earnings Release - 9:30AM EDT - Add to calendar
Aug 5, 2015
Q2 2015 Ophthotech Corp Earnings Call - 8:00AM EDT - Add to calendar
Jun 10, 2015
Ophthotech Corp at Goldman Sachs Healthcare Conference
Jun 4, 2015
Ophthotech Corp Annual Shareholders Meeting
May 21, 2015
Ophthotech Corp Annual Shareholders Meeting (Estimated)
May 18, 2015
Ophthotech Corp at UBS Global Healthcare Conference
May 13, 2015
Ophthotech Corp at Bank of America Merrill Lynch Health Care Conference
May 11, 2015
Q1 2015 Ophthotech Corp Earnings Call
May 11, 2015
Q1 2015 Ophthotech Corp Earnings Release
May 7, 2015
Ophthotech Corp at Deutsche Bank Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 15.92% -283.02%
Operating margin 18.08% -195.14%
EBITD margin - -194.83%
Return on average assets 5.44% -33.48%
Return on average equity 19.67% -78.30%
Employees 72 -
CDP Score - -


1 Penn Plz Fl 19
NEW YORK, NY 10119-0002
United States - Map
+1-212-8458200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ophthotech Corporation is a United States-based biopharmaceutical company. The Company is engaged in developing and commercializing therapies for the treatment of diseases of the eye and focuses on developing therapeutics for age-related macular degeneration (AMD). Its product pipeline includes Fovista anti-platelet derived growth factor (PDGF) therapy, which is in Phase III clinical trials for use in combination with anti-VEGF drugs to disrupt the formation of abnormal new blood vessels in wet AMD. It prevents PDGF from binding to its natural receptor on pericytes, thus causing pericytes to be stripped from newly formed abnormal blood vessels.Its second product candidate, Zimura, an inhibitor of complement factor C5, is developed for the treatment of geographic atrophy (a form of dry AMD) and, in combination with anti-VEGF therapy and Fovista, for the treatment of wet AMD. Both Fovista and Zimura are aptamers, single strands of nucleic acid that binds with affinity to targets.

Officers and directors

David R. Guyer Chairman of the Board, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Samir C. Patel M.D. Vice Chairman of the Board, President
Age: 54
Bio & Compensation  - Reuters
Barbara Wood Senior Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
Douglas K. Kollmorgen Senior Vice President - Quality Assurance
Bio & Compensation  - Reuters
Harvey N. Masonson M.D. Senior Vice President - Clinical Development
Bio & Compensation  - Reuters
Loni da Silva Senior Vice President - Global Regulatory Affairs
Bio & Compensation  - Reuters
Todd N. Smith Senior Vice President, Chief Commercial Officer
Age: 45
Bio & Compensation  - Reuters
Kathy Galante Vice President of Investor Relations and Corporate Communications
Bio & Compensation  - Reuters
Douglas G. Brooks Ph.D. Vice President - Manufacturing Development
Bio & Compensation  - Reuters
Jeffrey Nau Vice President - Clinical and Medical Affairs
Bio & Compensation  - Reuters